Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.1.7 (acetylcholinesterase)
28,390 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fosinopril is distinguished from other ACE inhibitors by a pharmacokinetic pecularity in the sense that is can be metabolized either by liver or kidney. This was the rationale of the present research the aim of which was to verify if administered to patients with liver cirrhosis the drug was liable to alter global liver function and ability to metabolize drugs. Eight cirrhotic males, mean age 56 years, also suffering from high blood pressure, were studied. In these patients, liver and kidney function tests (BUN, creatinine blood level, serum and urinary electrolytes, creatinine clearance, calcium and phosphor blood level, transaminases, alkaline phosphatase prothrombin time, cholinesterase, gamma-glutamyl-transpeptidase) were carried out at baseline and after 30 days' fosinopril treatment (1 capsule every morning in the fasting state); in addition total functioning liver mass was assessed by the galactose test, and drug-metabolizing capacity by the antipyrine test. Treatment resulted in a significant improvement of pressure values in all patients (p < 0.01) and did not alter liver and kidney function parameters. Besides, no side effects were registered, especially no case of orthostatic hypotension. The antipyrine test was not influenced by fosinopril treatment. Therefore, short-term treatment with this ACE-inhibitor can be concluded to be effective and not to cause additional alterations of liver function in patients with liver cirrhosis.
...
PMID:[Evaluation of the total hepatic function after treatment with fosinopril in hypertensive patients with liver cirrhosis]. 772 Mar 55

This study investigated the relationship between urinary sodium excretion and liver function, as assessed by the aminopyrine breath test (ABT) and conventional parameters, in 62 patients with cirrhosis kept on a constant salt diet. Urinary sodium excretion was related non-linearly to the ABT (r = 0.76). Less significant correlations were observed to the Child-Pugh score (r = -0.65), cholinesterase (r = 0.58), bilirubin (r = -0.56), albumin (r = 0.51) and prothrombin time (r = 0.49). When patients were arbitrarily divided into 6 groups according to the ABT, sodium excretion balanced the sodium intake up to a 50% reduction in ABT. In groups with more than a 50% reduction sodium retention occurred. When patients were grouped according to the Child-Pugh score, urinary salt output was balanced in patients with scores of 5 and 6 and decreased in patients with scores greater six. However, the change in sodium output from normal salt excretion to sodium retention was less pronounced in patients grouped according to the Child-Pugh score than in patients grouped according to the ABT. The results suggest a non-linear relationship between the impairment in hepatic and renal function in cirrhosis. They are compatible with the concept of a threshold of hepatic function necessary to maintain normal renal function.
...
PMID:Relationship of the aminopyrine breath test and the Child-Pugh score to urinary sodium retention in patients with liver cirrhosis. 775 46

Assessment of the galactose elimination capacity has appeared to represent an suitable index of the total metabolic capacity of the liver inflicted with chronic hepatopathy. In a more severe disease e.g. cirrhosis hepatis the GEC assessment enabled to judge appropriately the among of hepatic tissue reduction which does not necessarily have to correspond with the grade according to Child-Pugh classification. It represents an helpful criterion also for a smaller decrease of the functional capacity of the liver, e.g. in moderate forms of hepatopathies, as e.g. steatosis and steatofibrosis hepatis, chronic active hepatitis. By means of examinations of the hepatic proteosynthetic function indices it was discovered that the level of prealbumin and the activity of cholinesterase are more sensitive parameters of the functional ability of impaired liver in comparison with albumin, prothrombin complex and transferrin. Assessment of prealbumin and cholinesterase in the group of patients with cirrhosis hepatis enabled the most significant mutual distinction of differently severe grades, in three differing subgroups of cirrhotic patients (Ci A, Ci B and Ci C). The presented parameters were significantly distinct also in groups of patients with chronic active hepatitis, and steatosis and steatofibrosis of the liver. (Fig. 6, Tab. 1, Ref. 29.)
...
PMID:[The galactose eliminating capacity of the liver and its protein synthesis function in chronic liver diseases]. 781 45

A 10-yr-old boy with an injured lower extremity received sevoflurane anesthesia 5 times within 40 days. Laboratory tests for hepatic and renal function i.e., serum transaminase (glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, gamma-glutamyl transpeptidase), serum cholinesterase, plasma protein, serum cholinesterase, serum bilirubine, serum lactic dehydrogenase, serum prothrombin time, blood urea nitrogen, serum creatinine, beta 2-microglobulin, N-acetyl-D-glucosamidase and 24 hr-creatinine clearance remained within normal ranges throughout his perioperative period. Repeated sevoflurane anesthesia did not exert any adverse effect on hepatic and renal function in this patient.
...
PMID:[Effects of repeated sevoflurane anesthesia on hepatic and renal function in a pediatric patient]. 781 13

We measured urokinase-type plasminogen activator (u-PA) plasma levels in patients with various chronic liver diseases, including hepatocellular carcinoma (HCC), also measuring these levels in healthy volunteers. Plasma u-PA levels in the group of patients with decompensated liver cirrhosis (mean modified Pugh score of 14 points) were markedly elevated and significantly higher than those in the patients with decompensated liver cirrhosis with HCC (modified Pugh score of 10 points), those with compensated liver cirrhosis with HCC, and those with compensated liver cirrhosis. Patients in all these three latter groups had moderately and significantly elevated u-PA levels compared to levels in the chronic hepatitis group and the healthy volunteers, but the levels were not significantly different from each other. There was no relationship between u-PA plasma level and the type of HCC tumor invasion or number or size of tumors. Significant correlations were found between u-PA plasma levels and the results of seven different liver function tests in three groups without associated HCC; u-PA antigen and prothrombin time (%), hepaplastin test (%), serum cholinesterase, serum albumin, serum total cholesterol, and indocyanine green clearance correlated negatively, while u-PA antigen and serum total bilirubin correlated positively. These results suggest that plasma u-PA is associated with deterioration of liver function but not with HCC invasion.
...
PMID:Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma. 787 70

Thirty-two crossbred (Suffolk x Rambouillet) wether lambs were used to examine the effectiveness of protein source (soybean meal [SBM] or fish meal [FM]) in alleviating decreased performance associated with dietary aflatoxin (AF) in growing lambs. After a 21-d adaptation period to concentrate diets, lambs were assigned to the following dietary treatments: 1) SBM, 0 mg of AF; 2) FM, 0 mg of AF; 3) SBM + 2.5 mg of AF/kg diet; or 4) FM+2.5 mg of AF/kg diet (two lambs/pen; four pens/treatment). Diets were fed 35 d, at which time AF was removed from the diet (except one pen/protein source) and lambs continued on study for an additional 32 d. On d 67, all lambs were killed and necropsied. Average daily gain, feed intake, and gain/feed were similar (P > .10) among lambs fed SBM or FM; however, lambs fed AF had lower (P < .01) feed intakes, daily gain, and gain/feed. Feed intake remained lower (P < .01) after AF was removed from the diet. Aflatoxin elevated (P < .01) aspartate amino transferase and gamma-glutamyl transferase activities and total protein and cholesterol concentrations while decreasing (P < .05) alkaline phosphatase, glucose, cholinesterase, albumin, inorganic phosphorus, iron, and total-iron-binding capacity. Hematocrit, white blood cell count, and prothrombin time increased (P < .01) in lambs fed AF. No AF or protein effects were seen on ruminal VFA, pH, or lymphocyte blastogenesis (P > .10).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Effect of aflatoxin in growing lambs fed ruminally degradable or escape protein sources. 805 74

A series of new peptidyl (alpha-aminoalkyl)phosphonate diphenyl esters containing the 4-amidinophenyl group were synthesized and tested as irreversible inhibitors for thrombin and other trypsin-like enzymes. These phosphonates irreversibly inhibited several coagulation enzymes and trypsin. Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)2 is the best human thrombin inhibitor in the series with a k(obs)/[I] value of 11,000 M-1 s-1, and it inhibits thrombin more than 5-fold more effectively than the other enzymes tested. Z-(4-AmPhGly)P(OPh)2 is the best inhibitor for plasma kallikrein with a k(obs)/[I] value of 18,000 M-1 s-1. Generally, the (4-AmPhGly)P(OPh)2 derivatives are better inhibitors of thrombin and trypsin than the corresponding (4-AmPhe)P(OPh)2 derivatives which contain an extra CH2 separating the amidinophenyl group from the peptide backbone. The amidino phosphonates did not inhibit acetylcholinesterase and were chemically stable in neutral buffers. In addition, the inhibited trypsin derivative did not regain any enzyme activity after removal of excess inhibitor and incubation in a pH 7.5 buffer for 1 day. Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)2 and D-Phe-Pro-(4-AmPhe)P(OPh)2 prolonged the prothrombin time ca. 2-fold and prolonged the activated partial thromboplastin time ca. 3-4-fold in human plasma at concentrations of 63 and 125 microM, respectively. The novel amidine-containing peptidyl phosphonates reported here are thus effective anticoagulants in vitro, and they may have utility for use in vivo.
...
PMID:Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases. 829 9

Alpha 1-Antitrypsin deficiency predisposes to pulmonary emphysema, liver cirrhosis and hepatocellular carcinoma. Anecdotal evidence and a large autopsy study suggest that severe lung and liver disease rarely coexist in the same subject, but this has not been studied in patients. Therefore we investigated 27 patients with severe alpha 1-deficiency (Pi ZZ) and pulmonary emphysema for signs of liver disease and impaired hepatic function. A subgroup of 7 patients underwent quantitative liver function tests. On physical examination or ultrasonography, cirrhosis or tumor was not suspected in any patient. Conventional liver function tests were completely normal in 17 patients. Elevated serum activities of gamma-glutamyltranspeptidase and/or aminotransferases were seen in 10 patients. In some, the elevation was only marginal and in none more than twice normal. The serum bilirubin concentration and activity of alkaline phosphatase were increased in 1 patient. Serum protein, albumin, fibrinogen, antithrombin III, alpha 1-fetoprotein concentrations, serum activities of cholinesterase and glutamate dehydrogenase, activated partial thromboplastin time and prothrombin time were normal in all patients. The indocyanine green half-life was abnormal only in 1 of 6 patients, suggesting that hepatic blood flow was not impaired in the study group. However, the lidocaine half-life and galactose elimination capacity, parameters of hepatic metabolization, were impaired in 4 and 6 of 7 patients, respectively. We conclude that liver disease or impaired liver function is not a clinically relevant problem in most patients with pulmonary emphysema due to alpha 1-antitrypsin deficiency. But results of quantitative liver function tests, although performed in only a small group of patients, suggest that hepatic metabolization might be impaired even in those patients who present with pulmonary disease.
...
PMID:Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (Pi ZZ). 873 89

A survival analysis was carried out based on the data of 190 male patients with alcoholic liver cirrhosis (Child A: 82.2%; Child B: 17.8%). Patients (mean age: 49.6 +/- 7.1 years) were examined during the period 1983-1990. Censoring in May 1993 was based on the recordings of the "Rentenversicherungsanstalten". There were no "drop-outs". During follow-up (mean: 4.2 years) 64 (33.7%) of the patients died. 13 potential prognostic variables were examined individually by drawing Kaplan-Meier curves and performing log-rank tests. Portal pressure, determined during hepatic vein catheterization as hepatic vein pressure gradient HVPG (P), size of esophageal varices, serum bilirubin, serum albumin, prothrombin time (Quick), thromboplastin time (PTT), cholinesterase (ChE) and Child scores were correlated to survival (p < 0.05), whereas age, gamma GT, IgA, drinking habits and additional diagnoses were not. A multivariate Cox regression analysis stepwise eliminated all but three variables: ChE, albumin and variceal size were included in the prognostic index PI of the final model. The usefulness of the model was tested by a cross validation method. No significant difference was found between estimated and observed survivorship functions. To compare the PI of the Cox model with Child's scores, ROC curves of sensitivity and specificity of predicting death within one, three and five years were constructed. Better prognostic efficiency was indicated for PI. Because ChE, albumin and the size of varices are determined as a routine in our clinic, we consider the construction of PI an advisable alternative to Child's classification.
...
PMID:Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification. 877 35

The objective of this prospective study was to assess the prognostic value of dynamic and static liver function tests and clinical symptoms in pediatric patients with chronic end-stage liver disease in a serial examination including three evaluations at 3-month intervals. Of the 24 patients entering the study, six were given transplants within the observation period of 10 months. Of the remaining 18 patients who were considered in the final evaluation, five died before transplantation was possible. The variables included in the analysis were monoethylglycinexylidide (MEGX) formation from lidocaine, bilirubin, albumin, and creatinine serum concentrations, catalytic serum concentration of cholinesterase (CHE), prothrombin time (PT), factors II and V, serum amino acids, body weight, and presence of ascites. In nonsurvivors (n = 5), MEGX serum concentrations 30 min after intravenous administration of lidocaine (1 mg/kg body weight) were < 10 micrograms/L at the first examination. Statistically significant differences between nonsurvivors and survivors were observed for initial MEGX test results (p = 0.0089) and serum bilirubin concentrations (p = 0.009), as well as for the last available MEGX and bilirubin data from each patient (p = 0.017 and 0.016, respectively). At a diagnostic sensitivity of 100%, the corresponding diagnostic specificities for MEGX and bilirubin from the first examination were 77 and 62%, respectively. These data show that consistently low MEGX test results < 10 micrograms/L, obtained 30 min after intravenous administration of lidocaine (1 mg/kg body weight), are a prognostically unfavorable sign in pediatric transplant candidates.
...
PMID:Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates. 885 54


<< Previous 1 2 3 4 5 6 7 8 Next >>

---